SCHEMBL23908270

SCHEMBL23908270

O=C(NC1(c2ccc(Br)cc2)COC1)c1ccc(F)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WDR91 A4D1P6 7/20 0.56
CYP1A2 P05177 2/20 0.45
CYP3A4 P08684 2/20 0.45
CYP2D6 P10635 2/20 0.45
NPC1 O15118 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MEN1 O00255 1/20 0.45
POLB P06746 1/20 0.45
KMT2A Q03164 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
CHRNA7 P36544 2/20 0.44
ADCY1 Q08828 1/20 0.42
HDAC3 O15379 3/20 0.42
HDAC1 Q13547 3/20 0.42
HDAC2 Q92769 3/20 0.42
HDAC6 Q9UBN7 2/20 0.42
ALDH1A1 P00352 1/20 0.41
NR1I2 O75469 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22438947 0.87 HDAC1 (0.49) CYP1A2CYP3A4CYP2D6NPC1SMN1; SMN2
SCHEMBL22439020 0.84 HDAC1 (0.48) CYP1A2CYP3A4CYP2D6NPC1SMN1; SMN2
SCHEMBL2718047 0.77 WDR91 (0.44) WDR91CHRNA7HDAC3HDAC1HDAC2
SCHEMBL22684758 0.75 WDR91 (0.43) WDR91HDAC3HDAC1HDAC2HDAC6
SCHEMBL12614912 0.74 CHRNA7 (0.47) WDR91CYP3A4CHRNA7HDAC3HDAC1
SCHEMBL22438959 0.72 WDR91 (0.57) WDR91HDAC3HDAC1HDAC2HDAC6
SCHEMBL22685191 0.72 WDR91 (0.43) WDR91CHRNA7HTR1AKCNH2
SCHEMBL22657409 0.71 HDAC1 (0.47) CYP1A2CYP3A4CYP2D6NPC1SMN1; SMN2
SCHEMBL20898569 0.70 WDR91 (0.39) WDR91SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL20358898 0.70 PDE2A (0.52) SMN1; SMN2MEN1POLBKMT2AHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3709986-B1 NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-11-01 EP disclosed
US-11498904-B2 Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors MERCK SHARP & DOHME LLC (US) 2022-11-15 US disclosed
US-20210317091-A1 NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317091-A1 NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS IDO1, IDO2, KYNU WDR91 1642/4885CYP1A2 170/4885CYP3A4 934/4885
US-11498904-B2 Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors IDO1, IDO2, INMT WDR91 1729/4885CYP1A2 284/4885CYP3A4 1181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.